David C. Linehan

1995–2025 年に発表

85
論文数
18,559
被引用数
72
h 指数
84
i10 指数

被引用数

David C. Linehan の年別被引用数1995 年: 被引用 5 件1996 年: 被引用 14 件1997 年: 被引用 11 件1998 年: 被引用 13 件1999 年: 被引用 21 件2000 年: 被引用 32 件2001 年: 被引用 45 件2002 年: 被引用 29 件2003 年: 被引用 34 件2004 年: 被引用 57 件2005 年: 被引用 79 件2006 年: 被引用 111 件2007 年: 被引用 129 件2008 年: 被引用 111 件2009 年: 被引用 114 件2010 年: 被引用 99 件2011 年: 被引用 89 件2012 年: 被引用 119 件2013 年: 被引用 142 件2014 年: 被引用 178 件2015 年: 被引用 179 件2016 年: 被引用 238 件2017 年: 被引用 269 件2018 年: 被引用 213 件2019 年: 被引用 747 件2020 年: 被引用 797 件2021 年: 被引用 906 件2022 年: 被引用 632 件2023 年: 被引用 493 件2024 年: 被引用 800 件2025 年: 被引用 364 件2026 年: 被引用 14 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,470 件、この内訳の 30.3%中国: 引用元論文 1,191 件、この内訳の 14.6%イギリス: 引用元論文 453 件、この内訳の 5.6%ドイツ: 引用元論文 432 件、この内訳の 5.3%イタリア: 引用元論文 398 件、この内訳の 4.9%フランス: 引用元論文 345 件、この内訳の 4.2%日本: 引用元論文 334 件、この内訳の 4.1%オランダ: 引用元論文 219 件、この内訳の 2.7%カナダ: 引用元論文 185 件、この内訳の 2.3%オーストラリア: 引用元論文 176 件、この内訳の 2.2%スペイン: 引用元論文 165 件、この内訳の 2%韓国: 引用元論文 149 件、この内訳の 1.8%
0%30.3%その他 20%

分野

  • Medicine55.9%
  • Immunology and Microbiology28.2%
  • Biochemistry, Genetics and Molecular Biology13%
  • Engineering1.2%
  • Neuroscience0.5%
  • Materials Science0.3%
  • その他0.9%

トピック

  • Pancreatic and Hepatic Oncology Research9.4%
  • Immune cells in cancer8.6%
  • Cancer Immunotherapy and Biomarkers8.1%
  • Immunotherapy and Immune Responses5.6%
  • Immune Cell Function and Interaction5%
  • Cancer Genomics and Diagnostics2.9%
  • その他60.4%

共著者

全論文

検索で開く
  1. CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating Macrophages and Improves Response to T-cell Checkpoint Immunotherapy in Pancreatic Cancer Models

    著者: , , , , , , , , , - Cancer Research 2014 被引用: 1,287

  2. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 778

  3. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

    著者: , , , , , , , , , , , , , , - Gut 2017 被引用: 481

  4. Immunologic Strategies in Pancreatic Cancer: Making Cold Tumors Hot

    著者: , , , - Journal of Clinical Oncology 2022 被引用: 311

  5. Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

    著者: , , , , , , , , , , , , , , , , , , - Cancer Research 2012 被引用: 941

  6. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

    著者: , , , , , , , , , , , , , , - Investigational New Drugs 2019 被引用: 182

  7. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis

    著者: , , , , , , , , , , , , , , - Clinical Cancer Research 2013 被引用: 613

  8. Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 被引用: 238

  9. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard F. Dunne, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, William C. Hahn, Alex K. Shalek, Andrew J. Aguirre, Jonathan A. Nowak, Brian M. Wolpin - Cancer Research 2022 被引用: 90

  10. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2015 被引用: 484

  11. Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer

    著者: , , , , , , , , - The Journal of Immunology 2009 被引用: 450

  12. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 159

  13. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Leona A. Doyle, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Angelica Laing, William C. Hahn, Matthew Meyerson, Charles S. Fuchs, Shuji Ogino, Jason L. Hornick, Aram F. Hezel, Albert C. Koong, Brian M. Wolpin - JAMA Oncology 2017 被引用: 269

  14. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance

    著者: , , , , , , , , , , , , , , - Nature Communications 2018 被引用: 213

  15. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer

    著者: , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2022 被引用: 74

  16. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan A. Nowak - Clinical Cancer Research 2022 被引用: 76

  17. Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma

    著者: , , , , , , , , , , - The Journal of Immunology 2002 被引用: 1,462

  18. Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

    著者: , , , , , - Annals of Surgical Oncology 2009 被引用: 898

  19. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

    著者: , , , , , , , , - Cancer Immunology Immunotherapy 2012 被引用: 278

  20. Recruitment of CCR2+tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancer

    著者: , , , , , , , , , - OncoImmunology 2018 被引用: 115

  21. The clonal evolution of metastatic colorectal cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Science Advances 2020 被引用: 77

  22. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity

    著者: , , , , , , , , , , , , , , , , , , , , , , - Gut 2021 被引用: 74

  23. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy

    著者: , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 68

  24. The Accordion Severity Grading System of Surgical Complications

    著者: , , - Annals of Surgery 2009 被引用: 672